CLINICAL_TRIALS ClinicalTrials.gov record update

Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03805594
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:48.433134+00:00
Published At: 2025-02-25T00:00:00+00:00
Record Updated At: 2025-02-25
Results Posted At: 2025-02-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Stage IV Prostate Cancer", "Stage IVA Prostate Cancer", "Stage IVB Prostate Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-02-25"
protocolSection.identificationModule.nctId: "NCT03805594"
protocolSection.identificationModule.officialTitle: "Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-02-25"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.